Terminated
PHASE2
INTERVENTIONAL
NCT00994214
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after 6 months of treatment.
Interventions
Name:
BIM 23A760
Type:
DRUG
Description:
Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
Primary Outcomes
Measure:
Percentage of Subjects With Mean GH ≤2.5 ng/mL and Normalised IGF-1
TimeFrame:
At Month 6
Description:
Trial Information
NCT ID
NCT00994214
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Ipsen
Last Updated
December 15, 2025